Aurora to Acquire Whistler A Company with an Iconic Brand, Offering Organic Certified Cannabis and Organic Certified Cannabis Derivatives TSX: ACB | NYSE

Aurora to Acquire Whistler

A Company with an Iconic

Brand, Offering Organic Certified Cannabis and Organic Certified Cannabis Derivatives

TSX: ACB | NYSE: ACB

EDMONTON, Jan. 14, 2019 /CNW/ - Aurora Cannabis

Inc. ("Aurora" or the "Company") (TSX: ACB) (NYSE: ACB) (Frankfurt: 21P; WKN: A1C4WM) announced today that

the Company has entered into a letter of intent ("LOI") to acquire all the issued and outstanding shares of privately

held Whistler Medical Marijuana Corporation ("Whistler"), in an all-share transaction valued at up to approximately $175

million, including certain milestone payments (the "Transaction").

Located in Whistler, British Columbia, Whistler

has developed one of Canada's most iconic cannabis brands, built on quality, award-winning organic certified BC bud. The Transaction

is expected to provide Aurora with a premium and differentiated organic certified product suite, expanding both its medical and

adult-use offerings, and reinforcing Aurora's presence in the well-established west coast cannabis market.

Whistler has developed a strong reputation

with patients and adult-use consumers alike for providing premium quality cannabis products. Founded in 2013, Whistler is one of

Canada's original ten licensed producers, and was the first licensed producer to obtain organic certification and sell a full suite

of organic certified cannabis products.

Whistler operates two indoor licensed production

facilities, with its first located in Whistler, British Columbia, and the second, a recently licensed, purpose-built, state-of-the-art

facility located a 20-minute drive from the Whistler facility. Once the second facility reaches full capacity (anticipated for

Summer 2019) the facilities are anticipated to have a combined production capacity of over 5,000 kg per year. Whistler sells medical

cannabis derivatives internationally to both Australia and the Cayman Islands, and through the addition of Aurora's deep experience

in completing EU GMP certified facilities and its large global distribution network, Aurora plans to pursue additional international

export opportunities.

Additional transaction highlights:

History of profitability driven by industry-leading

pricing: Whistler has achieved positive cash flow since 2015, with EBITDA margins in excess of 30%. By ensuring consistency,

quality, and maintaining its organic commitment, Whistler has achieved average selling prices in excess of 50% greater than the

average Canadian medical market, and maintains a similar premium to provinces for adult-use.

Organic Certified EU GMP compliant production: Whistler

is certified by the Fraser Valley Organic Producers Association (FVOPA) and conforms to International Organic Growing Standards.

Whistler's second facility is constructed in compliance with EU GMP standards which, upon certification, will enable the Company

to supply organic certified cannabis products to the European market.

Iconic Whistler brand: Through the premium quality

of its products, as well as the location association with Whistler, British Columbia, which receives over 2.7 million visitors

annually and consistently ranks as one of the top global travel destinations, Whistler has established an iconic brand that resonates

strongly across Canada and international markets.

Broad product portfolio: Whistler has commercialized

more than 30 flower varieties and strain-specific oil products, from an extensive genetics bank of over 150 strains.

Further strengthened presence in Western Canada: Already

one of the strongest performing companies in the Western Canadian adult-use markets along with the Aurora, AltaVie and San Rafael

'71 brands, Whistler will further add a premium organic certified brand with exceptional traction and visibility in British Columbia,

Canada's third most populous province.

Whistler's growing domestic footprint: In addition

to its existing supply arrangements in British Columbia, Saskatchewan and the Yukon, Whistler has received product requests from

Alberta, Manitoba, and Ontario.

Organic certified large-scale extraction: Whistler

has differentiated large-scale cold-water extraction technology and processes, creating a full suite of organic certified oil products

(including THCA, CBG, and high CBD oils).

Management Commentary

"This transaction adds an iconic, organic

certified BC-based brand with exceptional traction and a significant price premium in both the medical and retail markets,"

said Terry Booth, CEO of Aurora. "We intend to accelerate the completion of Whistler's Pemberton expansion project, and leverage

our domestic and international distribution channels to increase market reach for their exceptional products. Whistler has established

leadership in the organic cannabis market, and we look forward to welcoming Christopher and his team to the Aurora family."

Christopher Pelz, CEO and Founder of Whistler,

added, "With its commitment to the highest product quality standards, as well as its large footprint in both the Canadian

and international cannabis markets, Aurora is the ideal partner for Whistler to enhance our growth and margin profile. We feel

there is a strong cultural fit, and believe that Aurora is the right home for us to maintain our organic craft cultivation identity,

while being able to leverage the resources and capabilities of a large and rapidly growing global company."

Neil Belot, Chief Global Business Development

Officer of Aurora, added, "Whistler, the longest operating certified organic cannabis producer in Canada, has an exceptional

track record built on the consistent delivery of premium user experiences. This has resulted in strongly-rated products that command

among the highest prices in the Canadian adult consumer use industry, targeting the premium organic craft segment in both the consumer

and medical markets. Furthermore, as the only cannabis producer in the world-renowned resort town of Whistler, British Columbia,

the company has developed broad brand appeal, both across Canada and internationally."

The all-share transaction includes certain

milestone payments in relation to Whistler achieving certain operational objectives. Including these milestone payments, the all-share

transaction values Whistler at up to $175 million.

The closing of the transaction is subject to

customary closing conditions, including execution of definitive documentation, completion of satisfactory due diligence, receipt

of approval of the shareholders of Whistler, and receipt of applicable third party and regulatory approvals and the satisfaction

of other conditions customary in transactions of this nature.

Stoic Advisory Inc. is acting as financial

advisor and Norton Rose Fulbright Canada LLP is acting as legal advisor to Whistler Medical Marijuana Corp.

McMillan LLP is acting as legal counsel to

Headquartered in Edmonton, Alberta, Canada

with funded capacity in excess of 500,000 kg per annum and sales and operations in 22 countries across five continents, Aurora

is one of the world's largest and leading cannabis companies. Aurora is vertically integrated and horizontally diversified across

every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis

and hemp production, derivatives, high value-add product development, home cultivation, wholesale and retail distribution.

Highly differentiated from its peers, Aurora

has established a uniquely advanced, consistent and efficient production strategy, based on purpose-built facilities that integrate

leading-edge technologies across all processes, defined by extensive automation and customization, resulting in the massive scale

production of high quality product at low cost. Intended to be replicable and scalable globally, our production facilities are

designed to produce cannabis of significant scale, with high quality, industry-leading yields, and low per gram production costs.

Each of Aurora's facilities is built to meet EU GMP standards, and its first production facility, the recently acquired MedReleaf

Markham facility, and its wholly owned European medical cannabis distributor Aurora Deutschland, have achieved this level of certification.

In addition to the Company's rapid organic

growth and strong execution on strategic M&A, which to date includes 15 wholly owned subsidiary companies - MedReleaf,

CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses,

CanniMed Therapeutics, Anandia Labs, HotHouse Consulting, MED Colombia, Agropro, Borela, and ICC Labs - Aurora is distinguished

by its reputation as a partner and employer of choice in the global cannabis sector, having invested in and established strategic

partnerships with a range of leading innovators, including: Radient Technologies Inc. (TSXV: RTI), Hempco Food and Fiber Inc. (TSXV:

HEMP), Cann Group Ltd. (ASX: CAN), Micron Waste Technologies Inc. (CSE: MWM), Choom Holdings Inc. (CSE: CHOO), Capcium Inc. (private),

Evio Beauty Group (private), Wagner Dimas (private), CTT Pharmaceuticals (OTCC: CTTH), and Alcanna Inc. (TSX: CLIQ).

Aurora's Common Shares trade on the TSX and

NYSE under the symbol "ACB", and are a constituent of the S&P/TSX Composite Index.

For more information about Aurora, please visit

our investor website, investor.auroramj.com